152 related articles for article (PubMed ID: 17610040)
21. A comparison of four different alpha1-blockers in benign prostatic hyperplasia patients with and without diabetes.
Bozlu M; Ulusoy E; Cayan S; Akbay E; Görür S; Akbay E
Scand J Urol Nephrol; 2004; 38(5):391-5. PubMed ID: 15764250
[TBL] [Abstract][Full Text] [Related]
22. Efficacy and safety of two doses (10 and 15 mg) of alfuzosin or tamsulosin (0.4 mg) once daily for treating symptomatic benign prostatic hyperplasia.
Nordling J
BJU Int; 2005 May; 95(7):1006-12. PubMed ID: 15839922
[TBL] [Abstract][Full Text] [Related]
23. [The effectiveness of naftopidil in patients with benign prostatic hyperplasia evaluated by QOL index].
Nakatsu H; Naoi M; Sekiyama K; Hamano S; Suzuki N; Tanaka M; Murakami S
Hinyokika Kiyo; 2007 Jan; 53(1):13-8. PubMed ID: 17310763
[TBL] [Abstract][Full Text] [Related]
24. Short-term effects of crossover treatment with silodosin and tamsulosin hydrochloride for lower urinary tract symptoms associated with benign prostatic hyperplasia.
Miyakita H; Yokoyama E; Onodera Y; Utsunomiya T; Tokunaga M; Tojo T; Fujii N; Yanada S
Int J Urol; 2010 Oct; 17(10):869-75. PubMed ID: 20735791
[TBL] [Abstract][Full Text] [Related]
25. Nocturnal polyuria in patients with lower urinary tract symptoms and response to alpha-blocker therapy.
Koseoglu H; Aslan G; Ozdemir I; Esen A
Urology; 2006 Jun; 67(6):1188-92. PubMed ID: 16750254
[TBL] [Abstract][Full Text] [Related]
26. Changes in nocturia from medical treatment of benign prostatic hyperplasia: secondary analysis of the Department of Veterans Affairs Cooperative Study Trial.
Johnson TM; Jones K; Williford WO; Kutner MH; Issa MM; Lepor H
J Urol; 2003 Jul; 170(1):145-8. PubMed ID: 12796667
[TBL] [Abstract][Full Text] [Related]
27. Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: a prospective open-label long-term study using frequency-volume chart.
Kojima Y; Sasaki S; Imura M; Kubota Y; Hayashi Y; Kohri K
Neurourol Urodyn; 2012 Jan; 31(1):80-5. PubMed ID: 22038792
[TBL] [Abstract][Full Text] [Related]
28. Clinical comparison of selective and non-selective alpha 1A-adrenoceptor antagonists for bladder outlet obstruction associated with benign prostatic hyperplasia: studies on tamsulosin and terazosin in Chinese patients. The Chinese Tamsulosin Study Group.
Na YJ; Guo YL; Gu FL
J Med; 1998; 29(5-6):289-304. PubMed ID: 10503165
[TBL] [Abstract][Full Text] [Related]
29. Combination therapy with doxazosin and tenoxicam for the management of lower urinary tract symptoms.
Ozdemir I; Bozkurt O; Demir O; Aslan G; Esen AA
Urology; 2009 Aug; 74(2):431-5. PubMed ID: 19501883
[TBL] [Abstract][Full Text] [Related]
30. Significance of nocturnal hesitancy in treatment of men with lower urinary tract symptoms.
Ku JH; Um JM; Shin JW; Yang JH; Paick JS
Urology; 2006 May; 67(5):978-83. PubMed ID: 16698358
[TBL] [Abstract][Full Text] [Related]
31. Effects of three types of alpha-1 adrenoceptor blocker on lower urinary tract symptoms and sexual function in males with benign prostatic hyperplasia.
Yokoyama T; Hara R; Fukumoto K; Fujii T; Jo Y; Miyaji Y; Nagai A; Sone A
Int J Urol; 2011 Mar; 18(3):225-30. PubMed ID: 21272091
[TBL] [Abstract][Full Text] [Related]
32. Efficacy of combination therapy with tamsulosin and zolpidem on nocturia in patients with benign prostatic hyperplasia.
Miwa K; Nishino Y; Kikuchi M; Masue T; Moriyama Y; Deguchi T
Cent European J Urol; 2011; 64(4):232-5. PubMed ID: 24578900
[TBL] [Abstract][Full Text] [Related]
33. Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.
Sugaya K; Kadekawa K; Ikehara A; Nakayama T; Gakiya M; Nashiro F; Goya M; Hatano T; Ogawa Y
Int J Urol; 2003 Nov; 10(11):569-74; discussion 575. PubMed ID: 14633079
[TBL] [Abstract][Full Text] [Related]
34. [Clinical effects of increase in the loading dose of tamsulosin (from 0.2 mg to 0.3 mg) on urinary disturbance associated with benign prostate hyperplasia].
Hisamatsu H; Yamashita S
Hinyokika Kiyo; 2010 Jun; 56(6):297-300. PubMed ID: 20610919
[TBL] [Abstract][Full Text] [Related]
35. Ramelteon combined with an α1-blocker decreases nocturia in men with benign prostatic hyperplasia.
Kawahara T; Morita S; Ito H; Terao H; Sakata R; Ishiguro H; Tanaka K; Miyamoto H; Matsuzaki J; Kubota Y; Uemura H
BMC Urol; 2013 Jun; 13():30. PubMed ID: 23758651
[TBL] [Abstract][Full Text] [Related]
36. Intermittent alpha-blocker therapy in the treatment of men with lower urinary tract symptoms.
Kaplan SA; Reis RB; Cologna A; Suaid HJ; Martins AC; Kohn IJ; Te AE
Urology; 1998 Jul; 52(1):12-6. PubMed ID: 9671862
[TBL] [Abstract][Full Text] [Related]
37. Estimating the quality-of-life impact and cost-effectiveness of alpha-blocker and anti-muscarinic combination treatment in men with lower urinary tract symptoms related to benign prostatic hyperplasia and overactive bladder.
Verheggen BG; Lee R; Lieuw On MM; Treur MJ; Botteman MF; Kaplan SA; Trocio JN
J Med Econ; 2012; 15(3):586-600. PubMed ID: 22332704
[TBL] [Abstract][Full Text] [Related]
38. Efficacy of adding behavioural treatment or antimuscarinic drug therapy to α-blocker therapy in men with nocturia.
Johnson TM; Markland AD; Goode PS; Vaughan CP; Colli JL; Ouslander JG; Redden DT; McGwin G; Burgio KL
BJU Int; 2013 Jul; 112(1):100-8. PubMed ID: 23448285
[TBL] [Abstract][Full Text] [Related]
39. Rate and associated factors of solifenacin add-on after tamsulosin monotherapy in men with voiding and storage lower urinary tract symptoms.
Lee HN; Lee KS; Kim JC; Chung BH; Kim CS; Lee JG; Kim DK; Park CH; Park JK; Hong SJ
Int J Clin Pract; 2015 Apr; 69(4):444-53. PubMed ID: 25363606
[TBL] [Abstract][Full Text] [Related]
40. Correlation between Lower Urinary Tract Symptoms (LUTS) and sexual function in benign prostatic hyperplasia: impact of treatment of LUTS on sexual function.
Jung JH; Jae SU; Kam SC; Hyun JS
J Sex Med; 2009 Aug; 6(8):2299-304. PubMed ID: 19493292
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
